![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL
|
|
|
CROI 2022 Feb 11-16
Leonard Sowah1, Laura Smeaton2, Irena Brates2, Debika Bhattacharya3, Benjamin Linas4, Bruce Kreter5, Sandra Wanger-Cardoso6, Sunil Solomon7, Mark Sulkowski7, Gregory Robbins8 for the ACTG 5360 Team
1National Institute of Allergy and Infectious Diseases, Rockville, MD, USA, 2Harvard School of Public Health, Boston, MA, USA, 3University of California Los Angeles School of Medicine, Los Angeles, CA, USA, 4Boston University School of Medicine, Boston, MA, USA, 5Gilead Sciences Inc, Foster City, CA, USA, 6Instututo Nacional de Infectologia - Laboratorio de Pesquisa ClĂnica em HIV/AIDS, Rio de Janeiro, Brazil, 7Johns Hopkins Univeristy School of Medicine, 8Harvard Medical School, Boston, MA, USA
![0322221](../images/032222/032222-9/0322221.gif)
![0322222](../images/032222/032222-9/0322222.gif)
![0322223](../images/032222/032222-9/0322223.gif)
![0322224](../images/032222/032222-9/0322224.gif)
![0322225](../images/032222/032222-9/0322225.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|